 "Gennova Biopharmaceuticals ready with 7 mn Gemcovac-19 vaccine dosages")
Gennova Biopharmaceuticals Ltd on Wednesday said it is ready with 70 lakh dosages of its Gemcovac-19 vaccine, the first indigenously developed mRNA vaccine against COVID-19 to be approved for restricted emergency use in adults.
The company, which is a subsidiary of Emcure Pharmaceuticals Ltd, has an annual capacity of producing 200 million dosages of the vaccine and is awaiting the government's nod to roll it out in the market.
Gemcovac-19 had received Emergency Use Authorization (EUA) from the Drugs Controller General of India (DCGI) on Tuesday.
Addressing a virtual press conference, Gennova Biopharmaceuticals Ltd, Chief Operating Officer Samit Mehta said Gemcovac-19 is the first mRNA vaccine developed in India and only third mRNA vaccine to be approved for COVID-19 in the world.
In contrast to other mRNA vaccines that require to be stored at sub-zero temperatures, Gemcovac-19 can be stored at 2-8 degrees.
That makes it "unique in its deployability in countries like India" and other similar nations, Mehta said, highlighting the advantages of Gemcovac-19 in terms of logistics and transportation.
Also Read
Gemcovac-19 will be available for adults above 18 years of age. It is a two-dose vaccine to be administered intramuscularly with a gap of 28 days.
When asked about the company's ability to supply the vaccine, he said, depending on the government's stand, Gennova has "seven million (70 lakh) dosages ready for immediate supplies".
The company said it aims to produce around 40-50 lakhs of doses per month and the capacity can be quickly doubled.
Mehta said while Gennova has an annual capacity to produce 200 million formulation dosages, as for the Active Pharmaceutical Ingredient (API) of the vaccine, it has capacity to produce 500 million dosages annually and the plan is to double it to 1 billion dosages this year.
On the market roll out of Gemcovac-19, he said, it would depend on what stand the government takes, either for its procurement or to make it available in the private market.
Commenting on the pricing of the vaccine, Mehta said, "It has not been fixed. There is still an ongoing discussion with the government."
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)